TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Need for blood transfusion postoperatively
Endpoint domain: Adverse events/effects
Primary endpoint: Pin-track infection grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of GT HSV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete relief from vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mucin production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urine viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance dependence classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDS scores for dependence identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful withdrawal rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in palmitic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: recovery of perceived muscle soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDF during isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMD during isometric contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required for achieving cardioplegic arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients showing spontaneous heart beat recovery after reperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Revascularization of the target vessel at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Event-free survival at 250 days
Endpoint domain: Mortality/survival
Primary endpoint: incident pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOTPAR VPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean readmission time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endotracheal intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mothers' perceptions of chances of survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recall of disabilities
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: predicted length of neonatal stays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of major complications (MC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total length of stay in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: X-ray-induced chromosomal damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma folate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: anticipated pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of subjects colonized by Archaea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of sites colonized by Archaea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postinjection pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to MPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort level of diagnostic work up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total in-hospital costs
Endpoint domain: Resource use
Primary endpoint: Psychological General Well‐Being Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sabbatsberg Sexual Self‐Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse reactions to ionic contrast material
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical symptoms integrals
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean AUC(0-3h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in knowledge and sun protection habits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: rSBA-MenC titers ≥1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antipolyribosylribitol phosphate concentrations ≥0.15 µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage decrease in degree of joint contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean increase in range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IL-8 concentration as a marker for CPPE identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rates of ANC < 1.5 x 10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence rates of grade 3 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rates of grade 4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of providing benzoylecgonine-free urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prothrombotic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Analogue symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to try the vegetable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CK-MB elevation
Endpoint domain: Adverse events/effects
Primary endpoint: sleep latency/efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: global quality of recovery scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to meet hospital discharge criteria
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: oral opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Patient's satisfaction regarding analgesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of recurrent cardiovascular disease
Endpoint domain: Mortality/survival
Primary endpoint: digestibility of cocoa butter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neonatal bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperbilirubinemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: PLI (Plaque Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ulcer-free months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-care cost reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: clinical performance posttest scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reconsultations with new/unresolved symptoms or complications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Experience of fissure symptoms within the past year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for subsequent surgical treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase of platelet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevention of infections associated with chemotherapy-induced neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Shortening of neutropenia following high-dose chemotherapy and progenitor-cell transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Chemotherapy-associated anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: working memory improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Refreshing sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Microsatellite instability (MSI) prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of secondary allodynia in the proximal oesophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chest wall pain threshold (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Foot pain threshold (PT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of days with nasal secretion and/or blocked nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Episodes of upper respiratory tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IL-10 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TNF-alpha release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CAP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LS value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on composite measures of memory, learning, and global cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in informant-rated caregiver burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: mouth dryness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall mouth condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: back muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: running activity assessed by DRI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: children's skills improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glasgow Outcome Scale score at six months post injury
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical lung function postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Scores for subjective symptoms (pain, edema, venous claudication)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life parameters (bodily pain, emotional role)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Veno-arteriolar reflex improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sarcopenia Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skeletal muscle mass index (SMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effort-reward ratio
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ventricular-arterial coupling (VAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: End-systolic elastance (Ees)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death or a cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: Death or end-stage renal disease
Endpoint domain: Mortality/survival
Primary endpoint: Fatal or nonfatal stroke
Endpoint domain: Adverse events/effects
Primary endpoint: composite end point of death, myocardial infarction, and urgent revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Surface EMG activity of erector spinae musculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum irisin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-operative CPK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of gadolinium-enhanced lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of pathological oesophageal reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Emotional disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Consultation frequency with GP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: risk/need for intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cardiovascular death and all-cause mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Seizures absent without rescue therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of bacterial load in treated wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: peak exercise work rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean fibre cross‐sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA expression of IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular responses (HR and SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of fever greater than 100 degrees F
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate or severe fussiness
Endpoint domain: Adverse events/effects
Primary endpoint: Injection site redness or swelling
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate or severe injection site pain
Endpoint domain: Adverse events/effects
Primary endpoint: MRC dyspnea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgery Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from pain in the recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSV-2 seroconversion incidence
Endpoint domain: Mortality/survival
Primary endpoint: Suitability for endovascular repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: vBMD (volumetric Bone Mineral Density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone areas and area moments of inertia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid-thigh muscle area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BCC cleared
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absorption rate via Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of cavitated dentin carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Alkaline Phosphatase (tALP) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate Dehydrogenase (LDH) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee hyperextension times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking function (10-meter test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttreatment control self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Volume of fluids required for resuscitation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plaque volume normalized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: vessel volume normalized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative serum C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cortisol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burnout prevalence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: depersonalization improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Global assessment of therapy improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average pain intensity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematologic Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance problems, side‐effects, adverse drug reactions, or drug interactions
Endpoint domain: Adverse events/effects
Primary endpoint: Estimated annual drug cost avoidance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily neuroleptic doses converted to chlorpromazine equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating FFAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brain neurometabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean CT attenuation of the coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in anterior facial height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-Adjusted Life Days (QALD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effective rate in treating chronic or Pi-deficiency diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rate of routine scatologic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of fatigue
Endpoint domain: Adverse events/effects
Primary endpoint: mean DMFS increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of new lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment success at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IGAxBSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful effect at week 8
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: objective structured clinical examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in prescribing of antibiotics for acute respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in total CDLQI scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in PedsQL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Use of antiemetic medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Metabolic syndrome criteria fulfillment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cytokine levels (IL-6, IL-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Movement amplitude at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of S. aureus nasal carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of hand cultures positive for S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: drinking reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid peroxidation (TBARS levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antioxidant capacity (TAS levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kupperman index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menopause rating scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in carotid intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reporting and interpretation of findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival in lymph node-positive patients
Endpoint domain: Mortality/survival